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Abstract  
  
Widespread,  frequent  testing  is  essential  for  curbing  the  ongoing  COVID-19  pandemic.  Because  
its  simplicity  makes  it  ideal  for  widely  distributed,  high  throughput  testing,  RT-LAMP  provides  an  
attractive  alternative  to  RT-qPCR.  However,  most  RT-LAMP  protocols  require  the  purification  of  
RNA,  a  complex  and  low-throughput  bottleneck  that  has  often  been  subject  to  reagent  supply  
shortages.  Here,  we  report  an  optimized  RT-LAMP-based  SARS-CoV-2  diagnostic  protocol  for  
saliva  and  swab  samples.  In  the  protocol  we  replace  RNA  purification  with  a  simple  sample  
preparation  step  using  a  widely  available  chelating  agent,  as  well  as  optimize  key  protocol  
parameters.  When  tested  on  clinical  swab  and  saliva  samples,  this  assay  achieves  a  limit  of  
detection  of  10 5  viral  genomes  per  ml,  with  sensitivity  close  to  90%  and  specificity  close  to  
100%,  and  takes  45  minutes  from  sample  collection  to  result,  making  it  well  suited  for  a  
COVID-19  surveillance  program.   
  
Introduction  
  
Widespread  testing  is  seen  as  the  solution  for  preventing  the  spread  of  SARS-CoV-2,  but  
must  include  the  testing  of  asymptomatic  people  to  be  effective.  While  much  progress  has  
been  made  in  addressing  the  COVID-19  pandemic,  treatments  remain  limited  and  vaccines  
have  not  finished  deployment.  In  the  meantime,  societies’  best  option  for  containment  is  to  
follow  “test  and  trace”  approaches  where  those  recently  exposed  to  SARS-CoV-2  quarantine  
themselves  so  they  do  not  spread  the  virus  further.  However,  in  most  countries  including  the  US,  
tests  are  typically  administered  only  after  symptoms  develop.  A  growing  scientific  consensus  
holds  that  effective  epidemiological  approaches  for  containing  the  virus  must  also  include  
routine  testing  of  asymptomatic  people 1 .   
  
Testing  for  SARS-CoV-2  after  the  onset  of  symptoms  misses  a  crucial  window  of  
pre-symptomatic  infectivity.  Viral  loads  decrease  over  time  in  most  patients  hospitalized  with  
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SARS-CoV-2,  indicating  a  peak  in  viral  load  sometime  at  or  before  symptom  onset 2 .  This  is  
consistent  with  data  from  a  nursing  home  outbreak  showing  a  subpopulation  of  presymptomatic  
patients  with  very  high  viral  loads  (C t ~13.7-18)  that  was  not  seen  in  the  symptomatic  patients 3 .  
Similarly,  statistical  analysis  on  cases  of  transmission  comparing  time  between  symptom  onsets  
with  the  incubation  period  of  the  virus  inferred  a  peak  infectivity  0-1  days  before  symptom  
onset 4 .  If  viral  load  and  infectivity  peak  before  symptom  onset,  then  it  is  likely  that  a  patient  will  
have  spread  the  virus  before  they  are  able  to  quarantine  themselves.  In  this  vein,  modeling  
indicates  that  testing  will  only  be  effective  if  conducted  on  asymptomatic  individuals  across  the  
population 1 .  However,  operating  at  this  scale  places  significant  constraints  on  the  design  of  a  
test.   
  
The  most  common  and  effective  testing  method,  RT-qPCR,  suffers  from  high  costs,  a  
requirement  for  infrastructure  and  operational  complexity.  Polymerase  chain  reaction  
(PCR)  is  a  foundational  method  in  molecular  biology  whereby  short  DNA  “primers”  are  annealed  
to  a  DNA  template  of  interest,  extended  by  DNA  polymerase,  creating  a  copy  of  the  template,  
and  then  dissociated  at  high  temperature  to  begin  the  cycle  again.  Quantitative  polymerase  
chain  reaction  (qPCR)  couples  this  DNA  synthesis  to  fluorescence  using  a  DNA  binding  dye  or  
other  method,  which  allows  a  quantitative  readout.  By  comparing  the  number  of  cycles  
(doublings)  required  to  reach  a  measurable  fluorescence,  the  C t  value,  the  amount  of  template   
DNA  in  the  sample  can  be  roughly  quantified.  Reverse  Transcriptase  qPCR,  RT-qPCR,  adds  a  
reverse  transcription  reaction  to  the  beginning  in  order  to  target  RNA.  RT-qPCR  is  an  essential  
laboratory  method  and  highly  sensitive,  able  to  detect  down  to  10 3  SARS-CoV-2  genome  copies  
per  ml  in  clinical  swab  samples.  However,  the  assay  also  has  several  drawbacks  we  hope  to  
address  in  this  work.  The  first  aspect  to  improve  is  cost:  the  price  of  a  COVID-19  qPCR  test  is  
limiting  in  nearly  all  settings  and  ranges  from  $20  to  greater  than  $100  per  test.  A  second,  
related  aspect  is  equipment  to  run  the  qPCR  test,  which  can  cost  many  thousands  of  dollars.  A  
third  aspect  is  test  complexity:  an  RT-qPCR  test  requires  molecular  biology  expertise  to  conduct  
and  interpret,  which  restricts  its  execution  to  labs  equipped  with  this  expertise  (CLIA  labs  in  the  
USA).  The  resulting  logistical  challenge  of  collecting,  shipping,  and  processing  samples  from  
different  locations  at  these  limited  number  of  labs  increases  test  turnaround  time  and  reduces  
throughput.  An  ideal  test  would  be  cheap  and  simple  enough  to  conduct  at  the  point  of  care  in  
low  resource  settings.  
  
Other  limitations  of  the  general  testing  regime  include  RNA  extraction  and  sample  
collection.  RT-qPCR  and  other  methods  require  RNA  extraction  from  a  sample  before  use  in  
the  assay.  RNA  extraction  is  costly,  low  throughput,  subject  to  reagent  shortages,  and  requires  
molecular  biology  expertise  to  conduct,  which  makes  it  desirable  to  skip.  Additionally,  
nasopharyngeal  swabs  have  often  been  in  short  supply  and  are  painful  and  dangerous  to  
collect.  By  contrast,  saliva  collection,  which  is  non-invasive,  safer  to  collect,  and  not  dependent  
on  swabs  or  other  supplies,  yields  comparable  or  higher  viral  loads  compared  to  
nasopharyngeal  swabs 5 .  Thus,  an  ideal  assay  would  skip  RNA  extraction  and  could  be  run  on  
saliva.   
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A  surveillance  assay  need  not  be  as  sensitive  as  qPCR.  After  infection  is  established,  RNA  
viruses  enter  an  exponential  phase  during  which  viral  load  rises  from  undetectable  to  orders  of  
magnitude  higher  than  the  LOD  of  qPCR  in  as  little  as  1-2  days.  Based  on  this  fact,  
mathematical  modeling  suggests  that  diagnostic  tests  that  have  1000-fold  higher  LOD  than  
qPCR  can  still  be  effective,  if  individuals  are  tested  often  enough  to  catch  the  spike 1 .  Therefore,  
sensitivity  can  be  traded  off  to  satisfy  the  other  constraints.  
  
Colorimetric  RT-LAMP  can  address  many  of  the  key  issues  currently  limiting  testing.  
Colorimetric  Reverse  Transcriptase  Loop-mediated  Isothermal  Amplification  (RT-LAMP)  is  a  
method  for  detecting  a  specific  RNA  species  using  an  isothermal  polymerase  reaction.  In  this  
method,  primers  are  designed  such  that  a  target  RNA  triggers  a  chain  reaction  of  DNA  hairpin  
synthesis 6,7 ,  which  is  read  out  by  a  pH  sensitive  dye  that  turns  yellow  as  protons  are  released  by  
DNA  polymerization 8 .  Since  it  does  not  require  a  PCR  machine,  RT-LAMP  is  ideal  for  field  
testing  of  viral  infections  and  has  been  used  for  Ebola  diagnosis  and  surveillance  in  Guinea 9,10 ,  
for  tracking  Zika  virus  in  Brazilian  mosquito  populations 11 ,  and  for  COVID-19  diagnosis  during  
the  initial  outbreak  in  Wuhan  and  Shenyang,  China 12,13 .  Recent  work  has  solidified  RT-LAMP  as  
a  simple,  inexpensive,  and  sufficiently  sensitive  alternative  to  RT-qPCR  for  SARS-CoV-2  
detection 14–26 .  
  
Here,  adding  a  chelating  agent  and  optimizing  reaction  volume,  we  demonstrate  
significant  improvements  to  RT-LAMP.  First  we  show  that  the  non-hazardous  chelating  agent  
Chelex-100  can  be  used  to  prepare  saliva  samples  for  RT-LAMP,  similar  to  how  it  has  been  
used  to  prepare  complex  forensic  samples  for  PCR 27–29 .  By  sequestering  divalent  metal  cations,  
Chelex-100  protects  RNA  from  degradation  at  high  temperature.  Chelex-100  also  has  a  basic  
pH  which  reduces  sensitivity  to  variations  in  patient  saliva  pH  without  inhibiting  LAMP.  Second,  
we  found  that  larger  reaction  volumes  can  provide  greater  sensitivity.  With  these  optimizations,  
we  achieved  a  limit  of  detection  of  10 5  RNA  copies  per  ml  and  got  results  consistent  with   
RT-qPCR  on  clinical  swab  samples  with  C t  up  to  32,  yielding  a  sensitivity  near  90%  and   
specificity  near  100%  on  clinical  swab  and  saliva  samples.   
  
Results   
  
Chelex-100  can  partially  protect  RNA  from  high  temperature  degradation.   
  
We  first  set  out  to  eliminate  the  need  for  RNA  purification  from  saliva  samples.  To  create  
synthetic  samples  for  testing,  the  SARS-CoV-2  N  gene  (IDT  # 10006625)  was  in-vitro  
transcribed,  quantified  with  digital  PCR,  serially  diluted  in  10-fold  steps,  and  spiked  into  human  
saliva.  The  samples  could  then  be  treated  with  various  sample  preparation  techniques  and  
added  to  a  10  µl  colorimetric  RT-LAMP  reaction  for  readout,  for  which  we  used  a  previously  
published  primer  set  targeting  the  N  gene,  N2 22  (see  Methods).  We  explored  multiple   
approaches  to  inactivate  potential  inhibitors  in  the  samples,  including  proteinase  K  to  degrade  
protein-based  inhibitors  as  well  as  a  95C  heat  inactivation  step.   
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With  heat  inactivation,  we  confirmed  a  recently  reported  result  that  assay  sensitivity  was  
significantly  higher  when  RNA  is  added  after  saliva  has  been  heat  treated  than  before,  implying  
a  significant  amount  of  temperature-induced  degradation 17 (Figure  1,  second  and  third  panels).  
We  hypothesized  that  RNA  degradation  at  high  temperatures  is  caused  by  enhancement  of  
RNA  hydrolysis  by  divalent  metal  cations,  which  mediate  nuclease  activity  at  biological  
temperatures 30 .  These  cations  attack  phosphodiester  bonds,  cleaving  the  RNA  backbone 30 .  
However,  chelating  agents  can  sequester  these  cations.  In  particular,  the  chelating  agent  
Chelex-100  has  been  used  to  prepare  RNA  and  DNA  for  PCR  from  complex  forensic  samples  
such  as  blood  and  saliva 28,29 .  In  keeping  with  standard  Chelex-100  protocols,  synthetic  samples  
were  mixed  2:3  with  10%  wt/vol  Chelex-100  solution,  incubated  at  95C  for  10  minutes,  and  then  
assayed  with  RT-LAMP.  Using  this  sample  prep,  the  degradation  due  to  heat  inactivation  was  
reduced  100-fold  (Figure  1,  fourth  panel).  
  
  
  
Figure  1:  Chelex-100  partially  protects  RNA  from  heat  induced  degradation.  In  each  
tube,  yellow  colorimetric  readout  indicates  RT-LAMP  amplification.  To  prepare  the  samples,  
pure  RNA  was  spiked  into  saliva  at  a  1:10  dilution,  which  is  why  the  first  panel  is  offset  
relative  to  the  others.  The  limit  of  detection  (LOD,  yellow  circle)  of  RT-LAMP  on  saliva  
samples  is  10,000-fold  lower  if  spiked  RNA  is  added  after  heat  inactivation  (second  row)  than  
if  it  is  added  before  (third  row),  indicating  that  a  significant  amount  of  RNA  is  being  degraded  
as  a  consequence  of  the  heat.  Adding  a  chelating  agent,  Chelex-100,  to  the  saliva  before  
heat  inactivation  partially  protects  RNA  from  this  degradation  (fourth  row).   
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Optimization  of  Chelex-100  sample  preparation  
  
Temperature,  incubation  time,  and  Chelex-100  concentration  affect  sensitivity.  Starting  
from  a  base  protocol  which  used  a  10  minute  incubation  at  95C  with  a  10%  wt/vol  Chelex-100  
solution,  we  conducted  one  round  of  optimization  by  individually  varying  incubation  time  (Figure  
2A),  temperature  (Figure  2B),  and  Chelex-100  concentration  (Figure  2C),  and  compared  the  
resulting  limits  of  detection.  The  initial  incubation  time  and  temperature,  10  minutes  and  95C,  
respectively,  were  near  optimal.  However,  increasing  Chelex-100  concentration  from  10%  to  
30%  wt/vol  improved  assay  sensitivity  10-fold  (Figure  2C).  With  the  resulting  optimal  conditions,  
we  achieved  a  sensitivity  of  10 7  copies  per  ml  from  human  saliva  (Figure  2C).  However,   
SARS-CoV-2  genome  concentrations  in  patient  saliva  range  from  10 3  to  10 9  copies  per  ml 2,5 .    
Therefore,  we  sought  additional  optimizations  before  moving  to  clinical  samples.  
  
RT-LAMP  sensitivity  scales  with  sample  volume.  Since  RT-LAMP  is  an  all-or-nothing  
reaction,  its  sensitivity  should  be  proportional  to  the  total  number  of  template  molecules.  
Intuitively,  a  larger  volume  at  lower  sample  concentration  should  yield  a  similar  result  as  a  lower  
volume  at  higher  sample  concentration,  assuming  the  same  concentration  ⨉  volume  product.  
This  would  effectively  increase  sensitivity  at  higher  volumes.  To  test  this,  we  varied  the  
RT-LAMP  total  reaction  volume.  Surprisingly,  sensitivity  increased  super-linearly,  rather  than  
only  linearly,  as  expected,  over  reaction  volumes  of  10  to  100µl.  This  occurred  with  both  pure  
RNA  samples  and  human  saliva  samples  (Figure  2D).  100μl  reactions  with  the  Chelex-100 
sample  prep  yielded  LODs  in  saliva  of  10 5  copies  per  ml  or  better.  Further  increasing  the  
reaction  volume  to  250  μl  caused  an  increase  in  false  positives  (not  shown),  and  was  not  
pursued  further.   
  
Other  optimizations  failed  to  increase  sensitivity  beyond  10 5  RNA  copies  per  ml.  40  mM   
Guanidine  HCL  was  shown  in  other  work  to  increase  sensitivity  of  RT-LAMP 22 .  Also,  certain  
engineered  polymerase  and  reverse  transcriptase  enzymes  have  been  reported  to  be  especially  
resistant  to  inhibitors,  such  as  ThermoFisher  Superscript  IV  reverse  transcriptase  and  NEB  BST  
3.0  polymerase 31 .  Starting  from  the  optimized  assay,  we  added  each  of  these  components  to  the  
reaction  individually  (Figure  2E).  In  each  case,  the  resulting  LOD  was  the  same  or  worse  than  
the  base  assay .  Based  on  these  results,  and  the  sufficiency  of  10 5  copies/ml  for  recent  studies  
of  high  frequency  testing  strategies,  we  decided  to  go  forward  with  testing  on  clinical  COVID-19  
samples.   
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Chelex  RT-LAMP  measurement  of  unpurified  clinical  samples  strongly  correlated  with  
qRT-PCR  analysis  of  purified  RNA.  We  evaluated  the  protocol  on  clinical  throat  and  nose  
swabs,  collected  in  universal  or  viral  transport  media  (UTM/VTM)  for  analysis  by  the  Virology  
laboratory  at  the  Rambam  Health  Care  Campus  in  Haifa,  Israel.  We  compared  qRT-PCR  
analysis  of  purified  RNA  to  Chelex  RT-LAMP  analysis  of  the  same  samples  without  RNA  
 
Figure  2:  A  Chelex-100  based  sample  preparation  was  optimized  by  varying  parameters  
one  at  a  time.  Starting  from  an  initial  protocol  where  10%  wt/vol  Chelex-100  was  mixed  3:2  
with  sample  and  incubated  for  10  minutes  at  95  C,  individual  parameters  were  varied  and  the  
LOD  (yellow  circle)  was  compared.  We  found  that  (A)  a  10  minute  incubation  time,  (B)  a  95C  
incubation  temperature,  and  (C)  30%  wt/vol  Chelex-100  stock  solution  optimized  LOD.  
Additionally,  increasing  the  volume  of  the  RT-LAMP  reaction  from  10  µl  to  100  µl  increased  
sensitivity  by  at  least  100-fold  (D),  but  increasing  the  volume  further  caused  an  increase  in  
false  positives  (not  shown).  Based  on  reports  in  other  publications,  we  also  tried  adding  40  
mM  guanidine  HCL 22 ,  Superscript  IV  reverse  transcriptase,  and  Bst  3.0  to  increase  sensitivity,  
however  the  LOD  was  unchanged  by  these  additions  (E).  Based  on  these  experiments,  we  
called  the  final  sensitivity  at  10 5   copies/ml.   
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purification.  More  specifically,  we  chose  31  positive  and  31  negative  samples  that  had  been  
previously  routinely  analyzed  in  the  laboratory  by  RT-qPCR  (2019-nCoV  detection  kit,  Seegene,  
CA,  USA),  with  RNA  extracted  using  either  automated  NucliSENSE  easyMAG  or  using  a  
magLEAD  automated  extraction  platform.  The  RT-qPCR  analysis  produced  C t  values  ranging   
from  17  to  34.  We  then  analyzed  the  original  unpurified  material  for  the  same  samples.  For  each  
sample,  we  mixed  60  µl  of  the  sample  with  90  µl  30%  Chelex-100  solution,  and  heated  to  95C  
for  10  minutes.  Then,  we  added  10  µl  of  the  resulting  mixture  to  a  100  µl  RT-LAMP  reaction  with  
the  N2  primer  set  (Figure  3A).  One  negative  control  sample  of  sterile  UTM  was  included  in  each  
set  of  samples  (Figure  3A,  label  NC).  Among  the  31  negative  samples,  no  strong  positive  
outcomes  were  observed,  although  a  few  samples  showed  slight  orange  color  (Figure  3A,  
arrowheads).  By  contrast,  among  the  31  positive  samples,  27  showed  strong  color  change.  
Among  these,  all  21  of  the  samples  with  C t <28  correctly  showed  positive  results  (Figure  3B).  
These  results  indicate  a  strong  correlation  between  the  Chelex  RT-LAMP  measurement  on  
unpurified  samples  and  the  qRT-PCR  analysis  of  purified  RNA.  
  
Defining  sensitivity  as  the  fraction  of  positive  samples  that  were  returned  positive  by  the  assay,  
we  next  asked  whether  we  could  identify  a  quantitative  C t  threshold  separating  the  regime  with   
nearly  perfect  sensitivity  from  that  where  there  is  no  detection.  We  assumed  that  the  sensitivity  
of  the  diagnostic  as  a  function  of  C t  could  be  described  by  a  logistic  model  with  two  parameters:   
C 0 ,  defined  as  the  C t   value  where  sensitivity  S=½,  and  ꞵ,  the  slope  of  S  at  C 0 :  
  
We  fit  the  model  using  Bayesian  inference  (see  Methods),  yielding  a  posterior  distribution  with  a  
median  C 0  estimate  of  31.9  with  a  95%  confidence  interval  of  [29.8,  36.0],  and  a  median  ꞵ   
estimate  of  1/8.99  (95%  confidence  interval  [1/19.9,  1/4.66])  (Figure  3B-D).  More  precise  
parameter  estimates  will  require  additional  data.  However,  these  inferences  are  consistent  with  
the  assay  being  highly  robust  for  samples  with  C t  below  28  and  sensitive  enough  to  detect  at   
least  half  of  samples  with  C t   values  of  up  to  ~32.  
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This  protocol  correctly  identified  93%  of  positive  saliva  samples  and  100%  of  negative  
saliva  samples  in  a  test  of  emergency  room  patients.  As  approved  by  the  CMC  Institutional  
Review  Board,  patients  at  Catholic  Medical  Center  requesting  COVID-19  tests  volunteered  
saliva  samples  that  were  then  marked  with  the  positive  or  negative  result  of  the  PCR  test.  20  
negative  samples  and  14  positive  samples  were  then  assayed  with  the  protocol  developed  in  
this  paper  (see  Protocol),  using  the  N1  primer  set,  which  has  similar  sensitivity  to  the  N2  primer 
set 32 .  No  negative  samples  yielded  a  positive  readout  after  45  minutes,  however  13/14  positive  
samples  did  (93%,  Figure  4).  This  confirms  that  this  assay  can  be  used  as  a  simple,  direct  
means  to  test  saliva  samples  for  SARS-CoV-2.  
  
  
 
Figure  3:  Clinical  validation  of  RT-LAMP  diagnostic  on  swabs  in  VTM.  ( A)  31  RT-qPCR  
positive  and  31  RT-qPCR  negative  clinical  nose  and  throat  swab  samples  were  collected  and 
assayed  for  SARS-CoV-2  using  the  optimized  protocol.  27/31  of  the  positive  samples  gave  
positive  RT-LAMP  results,  with  all  21  positive  samples  with  C t  below  28  reading  positive,  and   
0/31  negative  samples  giving  positive  results.  (Note  that  some  negative  samples  did  show  
orange  color,  black  arrow).  (B)  Sensitivity  as  a  function  of  C t .  The  median  estimated  sensitivity  
and  95%  confidence  intervals  at  different  C t .  (C)  Posterior  distribution  for  C 0 .  (D)  Posterior  
distribution  for  β.  
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Discussion  
  
In  this  work,  we  optimized  a  SARS-CoV-2  detection  protocol  to  prepare  saliva  and  
nasopharyngeal  swab  specimens  for  RT-LAMP  without  RNA  purification.  The  use  of  high  
concentrations  of  Chelex-100  protected  RNA  from  heat  induced  degradation,  and  a  high  
temperature  incubation  inactivated  inhibitors  in  the  saliva.  An  increased  volume  of  the  RT-LAMP  
reaction  allowed  larger  sample  volumes  in  the  reaction,  which  yielded  increased  sensitivity.  
Altogether,  this  protocol  achieved  a  sensitivity  of  10 5  SARS-COV-2  RNAs  /  mL,  robustly   
detected  the  virus  in  samples  up  to  a  Ct  of  28,  and  was  able  to  detect  the  virus  in  samples  with  
Ct  up  to  32,  without  false  positives  in  negative  samples.   
  
This  protocol  enables  the  implementation  of  high  throughput  population  screening.  Saliva  
collection  is  safer,  easier,  and  less  invasive  than  swab  collection.  Since  Chelex-100  is  a  
non-hazardous  reagent,  it  can  be  included  in  self-collection  kits.  Once  samples  have  been  
collected,  they  can  be  quickly  heat  inactivated,  and  processed  in  parallel  on  PCR  plates,  
 
Figure  4:  Clinical  validation  of  RT-LAMP  diagnostic  on  saliva  samples.  20  negative  
saliva  samples  and  14  positive  saliva  samples  were  collected  from  patients  at  Catholic  
Medical  Center  in  Manchester,  NH  and  assayed  with  the  Chelex-100  based  RT-LAMP  
diagnostic.  0/20  negative  samples  gave  a  positive  result,  but  13/14  (93%)  positive  samples  
gave  a  positive  result.  
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allowing  many  reactions  to  be  conducted  at  a  time.  By  contrast,  many  alternative  diagnostic  
protocols  require  uncapping  of  samples,  mixing  of  additional  reagents  into  samples,  and  other  
kinds  of  sample  handling  such  as  centrifugation  to  purify  RNA  or  otherwise  prepare  the  sample  
for  the  assay.  By  making  this  sample  handling  unnecessary,  this  sample  prep  method  is  safer,  
faster,  and  higher  throughput.  
  
There  are  still  issues  to  be  worked  out.  A  limitation  of  this  protocol  is  that  the  increased  volume  
of  the  assay  leads  to  a  reaction  cost  of  ~$7.  This  cost  can  be  potentially  reduced  by  reducing  
the  volume  to  the  25  µl  to  achieve  ~$2  per  reaction,  albeit  with  reduced  sensitivity.  Additionally, 
use  of  open  source  enzymes 26,33  and  pooling  the  samples  could  further  reduce  costs.  As  the   
volume  of  LAMP  reaction  increases,  false  positive  results  seem  to  increase  in  frequency  which  
manifested  as  a  few  negative  samples  turning  orange  in  our  experiments  presented  here.  These  
problems  could  potentially  be  mitigated  by  the  inclusion  of  UDG/UTP  in  the  LAMP  reaction,  
which  others  have  used  successfully  to  reduce  false  positives 26 .  These  problems  could  also  be  
reduced  by  running  reactions  with  2  different  primer  sets,  which  should  increase  certainty  of  a  
positive  or  negative  result.   
  
With  the  current  surge  in  Covid-19  across  the  US  and  the  world  this  technology  could  prove  
very  helpful  to  fill  the  void  for  rapid,  affordable,  easily  deployable,  widely  distributed  testing.  
  
Acknowledgements  
  
This  project  was  supported  by  the  Caltech  Merkin  Institute  for  Translational  Research  and  the  
Israel  Science  Foundation  (grant  No.  3633/19)  within  the  KillCorona  –  Curbing  Coronavirus  
Research  Program.  James  Flynn  provided  his  own  funds  to  conduct  the  study  at  Catholic  
Medical  Center.  
  
Competing  interests  
  
The  authors  declare  no  competing  interests.   
  
Methods  
  
Bayesian  Inference  
  
The  Metropolis-Hastings  algorithm  was  used  to  sample  parameters  from  the  posterior  
distribution  of  ꞵ  and  C 0 ,  using  the  logistic  model  
..   
Priors  were  constructed  by  analyzing  the  expected  scale  of  the  parameters.  Since  it  was  
unlikely  that  this  LAMP  assay  did  significantly  worse  or  better  than  PCR,  a  Gaussian  prior  was  
chosen  for  C 0 ,  with  mean  30  and  standard  deviation  10.  For  the  ꞵ  prior,  we  noted  that  the  
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derivative  of  the  sensitivity  function  at  C t  =  C 0  is  -ꞵ  and  that  we  expected  the  sensitivity  to  drop    
from  around  1  at  C t =28  to  around  0  at  C t  =  35,  which  would  imply  the  scale  of  the  slope  is  on  the   
order  of  magnitude  of  1/7.  Thus,  the  ꞵ  prior  was  chosen  to  be  gaussian  with  mean  1/7,  with  
standard  deviation  equal  to  2/7,  to  allow  for  some  flexibility.  Both  priors  were  restricted  to  the  
positive  real  line.  Transition  probabilities  for  C 0  and  ꞵ  were  gaussian  with  mean  zero  and  
standard  deviation  of  1  and  .1,  respectively.  1  million  points  were  sampled  from  the  posterior   
distribution,  and  the  .05,  .5,  .95  quantiles  for  both  ꞵ  and  C 0   were  computed.  
   
Protocol  
  
Materials  
- Chelex-100  (Bio-Rad  #1421253)   
- WarmStart®  Colorimetric  LAMP  2X  Master  Mix  (NEB  #M1800S/#M1800L)   
- Nuclease  free  water  (VWR  #10220-398)   
- N2  primers:  
  
  
- N1  primers:  
  
  
Important  Note:  It  is  recommended  that  these  primers  (both  N1  and  N2)  be  PAGE  purified  for  
the  highest  sensitivity  and  lowest  off-target  amplification.   
N2-F3  ACCAGGAACTAATCAGACAAG  
N2-B3  GACTTGATCTTTGAAATTTGGATCT  
N2-FIP  
TTCCGAAGAACGCTGAAGCGGAACTGATTA 
CAAACATTGGCC  
N2-BIP  
CGCATTGGCATGGAAGTCACAATTTGATGGC 
ACCTGTGTA  
N2-LF  GGGGGCAAATTGTGCAATTTG  
N2-LB  CTTCGGGAACGTGGTTGACC  
N1-F3  TGGACCCCAAAATCAGCG   
N1-B3  GCCTTGTCCTCGAGGGAAT   
N1-FIP  
CCACTGCGTTCTCCATTCTGGTAAATGCACCC 
CGCATTACG   
N1-BIP  
CGCGATCAAAACAACGTCGGCCCTTGCCATGT 
TGAGTGAGA   
N1-LF  TGAATCTGAGGGTCCACCAAA   
N1-LB  GGTTTACCCAATAATACTGCGTCTT   
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Prepare  30%  wt/vol  Chelex  stock  solution:  
  
1. Add  4.5  g  Chelex-100  to  a  15  mL  tube  
2. Fill  with  deionized  water  up  to  15  mL  
3. Shake  to  mix  until  no  white  clumps  are  visible.  The  final  solution  should  look  like  a  milky  
slurry  that  settles  to  the  bottom  of  the  tube  relatively  quickly  (~  1-3  mins).  
  
Prepare  Primer  Master  Mix  
  
In  a  PCR  tube,  mix:  
1. 56  µl  nuclease  free  water  
2. 16  µl  N2-FIP  
3. 16  µl  N2-BIP  
4. 4  µl  N2-LF  
5. 4  µl  N2-LB  
6. 2  µl  N2-F3  
7. 2  µl  N2-B3  
  
This  gives  10  reactions  for  a  100  µl  volume  LAMP  reactions.  For  more  reactions,  these  numbers  
can  be  scaled  proportionally.  
  
Sample  preparation:  
  
For  100  µl  of  fresh  saliva/swab  in  VTM:  
  
1. Shake  Chelex-100  stock  solution  vigorously  to  resuspend  the  resin  (because  Chelex  is  
quick  to  settle,  it  should  be  reshaken  every  3  samples  or  so  if  they  are  being  done  in  
succession)  
2. Add  150  µl  of  the  resuspended  30%  Chelex-100  stock  solution  to  the  100  µl  saliva,  
pipette  up  and  down  to  mix  thoroughly.  
3. Incubate  samples  in  a  95  C  wet  bath  (or  thermocycler  or  aluminum  96-well  plate)   for  10  
minutes.  
4. While  the  Chelex-saliva  solution  is  heating,  prepare  a  mixture  of  
- 50  µl  Warmstart  Colorimetric  LAMP  Master  Mix  (thawed  on  ice)  
- 10  µl  N2  primer  master  mix  
- 30  µl  nuclease  free  water  
on  ice  for  each  sample.  
5. After  10  minutes,  remove  Chelex-saliva  solution  from  heat,  place  on  ice  for  2  mins.  
6. Spin  Chelex-saliva  solution  in  a  PCR  tube  mini  centrifuge  for  a  5  second  pulse.  
7. Pipette  10  µl  from  the  top  of  the  Chelex-saliva  supernatant  into  the  Lamp  mixture,  final  
volume  should  be  100  ul.  
8. Heat  the  final  lamp  mixture  at  65  C  for  30  minutes.  
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9. Readout:  yellow  =  positive,  pink  =  negative.  
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